Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -1.85 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -3.47 | -3.33 | 0.14 | 4.03% |
2024-05-02 | 2024-03 | -3.59 | -3.07 | 0.52 | 14.48% |
2024-05-02 | 2024-03 | -3.59 | N/A | N/A | N/A |
2024-02-22 | 2023-12 | -0.78 | 0.55 | 1.33 | 170.51% |
2024-02-22 | 2023-12 | -0.78 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Argus Research | Upgrade | Buy | Buy |
2023-08-03 | TD Cowen | Downgrade | Outperform | Market Perform |
2023-08-03 | RBC Capital | Upgrade | Outperform | Outperform |
2023-08-03 | B of A Securities | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-08-02 | Deutsche Bank | Downgrade | Buy | Hold |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-30 | AFEYAN NOUBAR BOGHOS | Director | 6.86M | Sale |
2022-12-27 | ANDRES JUAN | Chief Technology Officer | 12.80K | Sale |
2024-02-15 | BANCEL STEPHANE J | Chief Executive Officer | 21.08M | Sale |
2024-05-02 | BERENSON STEPHEN A. | Director | 22.20K | Conversion of Exercise of derivative security |
2023-12-05 | GARAY ARPA | Officer | 3.69K | Sale |
2024-09-02 | HOGE STEPHEN | President | 1.60M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 45.71M | 5.55B | 12.01% |
2023-06-29 | Vanguard Group Inc | 27.46M | 3.34B | 7.22% |
2023-06-29 | Blackrock Inc. | 24.16M | 2.94B | 6.35% |
2023-06-29 | State Street Corporation | 14.23M | 1.73B | 3.74% |
2023-06-29 | Flagship Pioneering Inc. | 12.89M | 1.57B | 3.39% |
2023-06-29 | Coatue Management LLC | 6.55M | 795.35M | 1.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.11M | 1.23B | 2.66% |
2023-05-30 | Vanguard International Growth Fund | 9.42M | 1.20B | 2.47% |
2023-06-29 | Vanguard 500 Index Fund | 7.81M | 948.38M | 2.05% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 6.46M | 730.48M | 1.70% |
2023-07-30 | Vanguard Specialized-Health Care Fund | 4.45M | 523.90M | 1.17% |
2023-05-30 | Fidelity 500 Index Fund | 3.70M | 472.16M | 0.97% |
Split | Date |
---|---|
1 : 10 | 2017-08-03 |
-
We will be at $250-$260 before earnings, and after earnings report, we will jump to the $300s. A lot of Investors are waiting for the first report to make sure $MRNA is a real solid investment.
New investors will make good money, but early investors let’s just say, are going to be extra happy. -
As soon the $185.99 is done. The $200 is next.
-
-
Some people posting here that they have found a stock way better than $MRNA.
That $OCGN crap over the last 5years has lost 99.23% of people’s money. It would it be 99.9999% if it didn’t jump in the last few weeks. Yes, go look at their charts, open the 5 year.
Totally opposite of $MRNA. Plus moderna is actually selling a vaccine and making billions. Yes, billions are already in the bank. We are not waiting for trials or hoping to have high efficacy or even looking for buyers. We have a solid vaccine and it is sold out. We are just waiting on FDA to give the green light to be able to add %50 more doses per vial. By the way I doubt they will say no.
$OCGN is essentially the twin stock of game stop. But with a huge difference. Game stop was shorted 112%. This $OCGN crap is only shorted 9%. Not even there they have a good setup for a short squeeze. It is a very bad choice. As you can also see how bad it was for the people that got into game stop after already jumped.
-
That $OCNG crap over the last 5years has lost 99.23% of people’s money. It would it be 99.9999% if it didn’t jump in the last few weeks. Yes, go look at their charts, open the 5 year.
Totally opposite of $MRNA. Plus moderna is actually selling a vaccine and making billions. Yes, billions are already in the bank. We are not waiting for trials or hoping to have high efficacy or even looking for buyers. We have a solid vaccine and it is sold out. We are just waiting on FDA to give the green light to be able to add %50 more doses per vial. By the way I doubt they will say no.
$OCNG is essentially the twin stock of game stop. But with a huge difference. Game stop was shorted 112%. This $OCNG crap is only shorted 9%. Not even there they have a good setup for a short squeeze. It is a very bad choice. As you can also see how bad it was for the people that got into game stop after already jumped.
-
That $OCNG crap over the last 5years has lost 99.23% of people’s money. It would it be 99.9999% if it didn’t jump in the last few weeks.
Totally opposite of $MRNA.
$OCNG is essentially the twin stock of Game stop. Now you know
-
By the way, when you get the vaccine. The only one protected is you. You can still get COVID-19 and spread it. With the vaccine you just act like a asymptomatic and have the 94-95% chances to be fine. With the other vaccines your chances are less and you might end up getting sick anyway.
-
-
That’s is because they want Moderna investors and traders to go to their stocks promising that they will sell more vaccines than Moderna.
The thing is if you get out of moderna before earnings. You will miss the biggest jump Moderna have done. So, just be smart or you can go and someone else will buy your share and make the money -
Bears are just playing with fire right now. And they are about to get burned.
The big news is coming out over the weekend. -
-
Is that the little pullback we needed to finally sprint to the $180?
-
Come on, let’s just cross the $178. After that old bears will give up and new bears will start suffering. Is part of the game.
-
Guys.
In this moment we witness to one of the most important catalyst in the vaccines industry for 2021.
OCGN. OMG.They came from nowhere and they look so promise IMO.
Nice weekend my fellows American
-
Shorts, buyers and sellers. But that is part of the game. Someone has to lose. Bears are just holding the stock back, but not for long. Next week we will be in the $200+ and old bears will give up while new ones will come in. But new buyers also will come in.
-
NVAX 19B vs MRNA 69B. Doesn’t make sense mathematically. NVAX has more orders in the book. In fact 2 nd in place after AZ. But NVAX will move up to #1 as Sanofi dropped.
-
By the time other players start selling. The biggest markets are already taken by $MRNA and $PFE. Unless other companies come with a 95% or higher efficacy, rich countries won’t buy their vaccines. Remember, to win a market, you need to be equal or better than what is out there, plus you have to sell cheaper.
$MRNA is just waiting on FDA approval to flood the market with 50% more doses without any extra effort. Now that is the news we all are waiting today or the weekend.
After that it will be earnings report in less than 3 weeks. -
I see, the new bears that got in last Friday are fighting the $174.99. Too bad, Bank of America already help them very nicely, if they didn’t take profits, now is their chance to cover and break even.
-
I hope today it is just the bears and the bulls going at it. Save the 50% dose increase per vial for the weekend. That way on Monday we get the 20% jump.
Well either way the 20% run or jump is coming. Just look a Novavax, it went from $130 fo $290!!
-
NTx Services Launches to Supercharge Next Generation mRNA Research
businesswire.com • -
Moderna (NASDAQ:MRNA) Shares Up 7%
news.google.com • -
Moderna (NASDAQ:MRNA) PT Lowered to $48.00
news.google.com • -
What's Going On With Moderna Shares Tuesday?
news.google.com • -
Where are the Opportunities in (MRNA)
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
Moderna (MRNA) Rises Higher Than Market: Key Facts
news.google.com • -
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein
news.google.com • -
Moderna's Recent Drop: 4 Reasons Bulls See Opportunity
marketbeat.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Moderna: Cutting Costs At Just The Worst Time (NASDAQ:MRNA)
news.google.com • -
Class Action Lawsuit Against Moderna, Inc. (NASDAQ:MRNA)
news.google.com • -
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
news.google.com • -
Moderna Gets Analyst Downgrade After $1.1B R&D Spending Cut
news.google.com • -
‘Time to Move to the Sidelines,’ Says Jefferies About Moderna Stock
news.google.com • -
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
news.google.com • -
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts
news.google.com • -
Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline (NASDAQ:MRNA)
news.google.com • -
Moderna: Looking For The Bottom (NASDAQ:MRNA)
news.google.com • -
Moderna stock slides on downgrades tied to profitability delay
news.google.com • -
Moderna Stock Falls Again. How the Drug Maker Can Turn Things Around.
news.google.com • -
Moderna: Oddo BHF reduces its target after CMD
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Moderna (NASDAQ:MRNA) Stock Falls 12% as R&D Budget Is Cut by $1B
news.google.com • -
Big Rate Cut or Small, U.S. Stocks Are Priced for Middling Returns
news.google.com • -
Moderna Stock Hits Lowest Since 2020. What’s Behind the Tumble.
news.google.com • -
Biggest stock movers today: MPW, MRNA, NTGR, and more
news.google.com • -
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
news.google.com • -
Moderna Stock Plummets on Cost-Cutting Measures
news.google.com • -
Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know
news.google.com • -
Biggest stock movers today: WBD, MPW, MRNA, SIG, and more
news.google.com • -
Moderna stock plunges after slashing R&D budget
news.google.com • -
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
news.google.com •